drugset / Trial / NCT01293539
Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to show that chemotherapy delivered directly through the artery supplying the eye (ophthalmic artery) to patients with retinoblastoma is a safe and effective treatment alternative to conventional systemic chemotherapy, external beam radiation, and surgical removal of the eye.
Timeline
- Start
- 2011-03
- Primary completion
- 2016-08
- Completion
- 2016-08
Outcome
Outcome not reported
Stopped: “IAC is now recognized as part of standard of care treatment options in the US.”
Publications
- Background Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008 Aug;115(8):1398-404, 1404.e1. doi: 10.1016/j.ophtha.2007.12.014. Epub 2008 Mar 14.
- Background Abramson DH. Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol. 2011 Nov;129(11):1492-4. doi: 10.1001/archophthalmol.2011.354. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 2.5 mg | Other |
| Subject | Melphalan | Small molecule | 3 mg | Other |
| Subject | Melphalan | Small molecule | 4 mg | Other |
| Subject | Melphalan | Small molecule | 5 mg | Other |